631 related articles for article (PubMed ID: 32747829)
1. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Nat Med; 2020 Oct; 26(10):1549-1556. PubMed ID: 32747829
[TBL] [Abstract][Full Text] [Related]
2. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
[TBL] [Abstract][Full Text] [Related]
4. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
DiGennaro J; Sallman DA
Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
[TBL] [Abstract][Full Text] [Related]
5. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
6. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
10. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
11. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
12. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
Venugopal S; Loghavi S
Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
[TBL] [Abstract][Full Text] [Related]
13. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
15. Transplant for TP53-mutated MDS and AML: because we can or because we should?
Versluis J; Lindsley RC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):522-527. PubMed ID: 36485102
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK
Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128
[TBL] [Abstract][Full Text] [Related]
17.
Ball S; Loghavi S; Zeidan AM
Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
[TBL] [Abstract][Full Text] [Related]
18. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
